Gladstone Institutional Advisory’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$240K Sell
1,483
-200
-12% -$33.3K 0.01% 886
2026
Q2
$319K Buy
+1,683
New +$317K 0.01% 721
2026
Q1
– Sell
-1,172
Closed -$215K – 836
2025
Q4
$215K Buy
+1,172
New +$206K 0.01% 739
2025
Q2
– Sell
-1,438
Closed -$211K – 756
2025
Q1
$211K Buy
+1,438
New +$208K 0.01% 681
2024
Q4
– Sell
-1,447
Closed -$225K – 699
2024
Q3
$225K Buy
1,447
+100
+7% +$16.1K 0.01% 627
2024
Q2
$210K Buy
+1,347
New +$203K 0.01% 616
2022
Q2
– Sell
-1,605
Closed -$213K – 653
2022
Q1
$213K Sell
1,605
-377
-19% -$45.2K 0.01% 654
2021
Q4
$231K Buy
+1,982
New +$233K 0.02% 530
2020
Q4
– Sell
-3,281
Closed -$360K – 302
2020
Q3
$360K Buy
+3,281
New +$365K 0.09% 175

Other funds holding AZN

Gladstone Institutional Advisory's AZN Position: Q3 2026 in Review

Gladstone Institutional Advisory reduced its AstraZeneca (AZN) stake by 12% in Q3 2026, selling an estimated $33.3K and leaving 1,483 shares worth $240K. The position accounts for 0.01% of the portfolio, ranked #886.

Gladstone Institutional Advisory first reported a position in AZN in Q3 2020 and has held it in 9 quarters since. The position peaked at $360K in Q3 2020. 1,446 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Gladstone Institutional Advisory held 1,483 shares of AstraZeneca worth $240K as of Q3 2026.
  • Gladstone Institutional Advisory sold 200 AstraZeneca shares in Q3 2026, an estimated $33.3K.
  • AstraZeneca made up 0.01% of Gladstone Institutional Advisory's portfolio in Q3 2026, its #886 holding.
  • Gladstone Institutional Advisory first reported a position in AstraZeneca in Q3 2020 and has held it in 9 quarters since.
  • Gladstone Institutional Advisory's AstraZeneca position peaked at $360K in Q3 2020.
  • 1,446 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Gladstone Institutional Advisory's 13F filing for Q3 2026, filed 13 Nov 2026.